NEW YORK (GenomeWeb) – Trovagene has secured a $15 million unrestricted debt facility from Silicon Valley Bank and Oxford Finance, the company said on Tuesday.

The San Diego-based firm will use the capital to support development and commercialization of its urine-based cell-free oncogene mutation cancer monitoring technology.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.